EA201991870A1 - Лечение рака мочевого пузыря с помощью антитела к pd-l1 - Google Patents

Лечение рака мочевого пузыря с помощью антитела к pd-l1

Info

Publication number
EA201991870A1
EA201991870A1 EA201991870A EA201991870A EA201991870A1 EA 201991870 A1 EA201991870 A1 EA 201991870A1 EA 201991870 A EA201991870 A EA 201991870A EA 201991870 A EA201991870 A EA 201991870A EA 201991870 A1 EA201991870 A1 EA 201991870A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bladder cancer
antibody
subject
methods
treatment
Prior art date
Application number
EA201991870A
Other languages
English (en)
Russian (ru)
Inventor
Джон Кёрланд
Джон Эндрю Блейк-Хэскинс
Магдалена Зеджек
Марлон РЕБЕЛАТТО
Ашок Гупта
Тони Хо
Джилл Уокер
Сяопин Чжин
Шеннон Моррис
Роберт Ианнон
Ли ШИ
Мохаммед Дар
Юн Бен
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of EA201991870A1 publication Critical patent/EA201991870A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201991870A 2017-02-16 2018-02-16 Лечение рака мочевого пузыря с помощью антитела к pd-l1 EA201991870A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Publications (1)

Publication Number Publication Date
EA201991870A1 true EA201991870A1 (ru) 2020-02-12

Family

ID=63169615

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991870A EA201991870A1 (ru) 2017-02-16 2018-02-16 Лечение рака мочевого пузыря с помощью антитела к pd-l1

Country Status (12)

Country Link
US (2) US20190359715A1 (enExample)
EP (1) EP3582805A4 (enExample)
JP (2) JP2020507596A (enExample)
KR (3) KR20230145547A (enExample)
CN (2) CN110290803A (enExample)
AU (2) AU2018221822A1 (enExample)
CA (1) CA3052652A1 (enExample)
EA (1) EA201991870A1 (enExample)
IL (3) IL320916A (enExample)
MA (1) MA47509A (enExample)
SG (1) SG11201907211TA (enExample)
WO (1) WO2018152415A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP2023526400A (ja) * 2020-05-21 2023-06-21 アストラゼネカ・アクチエボラーグ 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量
WO2026003724A1 (en) * 2024-06-25 2026-01-02 Astrazeneca Ab Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
KR20170132171A (ko) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
EP3303632B2 (en) * 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie

Also Published As

Publication number Publication date
IL268460A (en) 2019-09-26
KR20250025517A (ko) 2025-02-21
CA3052652A1 (en) 2018-08-23
SG11201907211TA (en) 2019-09-27
IL302777A (en) 2023-07-01
JP2024038034A (ja) 2024-03-19
US20220332828A1 (en) 2022-10-20
IL320916A (en) 2025-07-01
EP3582805A4 (en) 2021-03-10
MA47509A (fr) 2019-12-25
CN118001389A (zh) 2024-05-10
EP3582805A1 (en) 2019-12-25
AU2025201227A1 (en) 2025-03-13
AU2018221822A1 (en) 2019-09-26
KR20230145547A (ko) 2023-10-17
JP2020507596A (ja) 2020-03-12
KR20190117014A (ko) 2019-10-15
WO2018152415A1 (en) 2018-08-23
US20190359715A1 (en) 2019-11-28
CN110290803A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
CO2017001317A2 (es) Composición farmacéutica con anticuerpos anti cd40 y kit
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2021008888A (es) Anticuerpos anti-tau humanizados.
PH12016501384B1 (en) Human antibodies to pd-l1
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EP4589014A3 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
EA201992575A1 (ru) Биомаркеры для терапии рака
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
EA201992522A1 (ru) КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112022010934A2 (pt) Métodos para tratar copd administrando um antagonista de il-33
EA201792286A1 (ru) Способы лечения рака
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5